Compare ACGLN & OSRHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | ACGLN | OSRHW |
|---|---|---|
| Founded | N/A | N/A |
| Country | Bermuda | United States |
| Employees | 8000 | 22 |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | 2023 |
| Metric | ACGLN | OSRHW |
|---|---|---|
| Price | $17.25 | $0.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 46.4K | 31.0K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.30 | $0.03 |
| 52 Week High | $18.34 | $0.08 |
| Indicator | ACGLN | OSRHW |
|---|---|---|
| Relative Strength Index (RSI) | 63.47 | 41.54 |
| Support Level | $16.46 | $0.04 |
| Resistance Level | $17.93 | $0.06 |
| Average True Range (ATR) | 0.25 | 0.01 |
| MACD | 0.11 | -0.00 |
| Stochastic Oscillator | 94.34 | 56.58 |
Arch Capital Group Ltd is a Bermuda company that writes insurance and reinsurance with operations in the United States, Canada, Europe, Australia, and the United Kingdom. The business operates through three underwriting segments: insurance, reinsurance, and mortgage. The insurance segment provides specialty risk solutions to clients across various industries. The reinsurance segment provides reinsurance services which cover property catastrophe, property, liability, marine, aviation and space, trade credit and surety, agriculture, accident, life and health, and political risk. The mortgage business provides risk management and risk financing products to the mortgage insurance sectors through platforms in the U.S., Europe and Bermuda.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.